Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1160959-64-7

C58H54N14O12S6 is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1160959-64-7 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1160959-64-7 Structure

  • Basic information

    1. Product Name: C58H54N14O12S6
    2. Synonyms:
    3. CAS NO:1160959-64-7
    4. Molecular Formula:
    5. Molecular Weight: 1331.55
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 1160959-64-7.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: N/A
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: C58H54N14O12S6(CAS DataBase Reference)
    10. NIST Chemistry Reference: C58H54N14O12S6(1160959-64-7)
    11. EPA Substance Registry System: C58H54N14O12S6(1160959-64-7)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1160959-64-7(Hazardous Substances Data)

1160959-64-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1160959-64-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,6,0,9,5 and 9 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1160959-64:
(9*1)+(8*1)+(7*6)+(6*0)+(5*9)+(4*5)+(3*9)+(2*6)+(1*4)=167
167 % 10 = 7
So 1160959-64-7 is a valid CAS Registry Number.

1160959-64-7Upstream product

1160959-64-7Downstream Products

1160959-64-7Relevant articles and documents

Discovery of LFF571: An investigational agent for Clostridium difficile infection

Lamarche, Matthew J.,Leeds, Jennifer A.,Amaral, Adam,Brewer, Jason T.,Bushell, Simon M.,Deng, Gejing,Dewhurst, Janetta M.,Ding, Jian,Dzink-Fox, Joanne,Gamber, Gabriel,Jain, Akash,Lee, Kwangho,Lee, Lac,Lister, Troy,McKenney, David,Mullin, Steve,Osborne, Colin,Palestrant, Deborah,Patane, Michael A.,Rann, Elin M.,Sachdeva, Meena,Shao, Jian,Tiamfook, Stacey,Trzasko, Anna,Whitehead, Lewis,Yifru, Aregahegn,Yu, Donghui,Yan, Wanlin,Zhu, Qingming

, p. 2376 - 2387 (2012)

Clostridium difficile (C. difficile) is a Gram positive, anaerobic bacterium that infects the lumen of the large intestine and produces toxins. This results in a range of syndromes from mild diarrhea to severe toxic megacolon and death. Alarmingly, the prevalence and severity of C. difficile infection are increasing; thus, associated morbidity and mortality rates are rising. 4-Aminothiazolyl analogues of the antibiotic natural product GE2270 A (1) were designed, synthesized, and optimized for the treatment of C. difficile infection. The medicinal chemistry effort focused on enhancing aqueous solubility relative to that of the natural product and previous development candidates (2, 3) and improving antibacterial activity. Structure-activity relationships, cocrystallographic interactions, pharmacokinetics, and efficacy in animal models of infection were characterized. These studies identified a series of dicarboxylic acid derivatives, which enhanced solubility/efficacy profile by several orders of magnitude compared to previously studied compounds and led to the selection of LFF571 (4) as an investigational new drug for treating C. difficile infection.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1160959-64-7